Reports Q1 revenue $40.5M, consensus $39.14M. “With continued strength in our market-leading OA Pain Management platform, an expanding and highly differentiated HA-based regenerative solutions pipeline, and continued cost discipline, we delivered a good start to the year and are on track to achieve our 2024 guidance,” said Cheryl R. Blanchard, Ph.D., Anika’s President and CEO. “While we are still early in the execution of our refocused strategy, we are pleased with the results and poised to capture the opportunities ahead as we seek to maximize value for our shareholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIK:
- Anika Therapeutics Announces New CFO and Executive Changes
- Anika Announces CFO Transition
- ANIK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Medicare Administrators looking to ‘drastically shake up’ wound care, says BTIG